Brief: Sanofi: Acoziborole Winthrop Receives CHMP Positive Opinion
27/02/2026 10:59
Feb 27 (Reuters) - Sanofi SA SASY.PA: PRESS RELEASE: ACOZIBOROLE WINTHROP, DEVELOPED BY DNDI AND SANOFI, RECEIVES CHMP POSITIVE OPINION AS THREE-TABLET, SINGLE-DOSE TREATMENT FOR MOST COMMON FORM OF SLEEPING SICKNESS PHASE 2/3 STUDY SHOWS 96% SUCCESS RATE FOR T.B. GAMBIENSE TO DONATE MEDICINE TO WHO THROUGH FOUNDATION S ACOZIBOROLE RECEIVES CHMP POSITIVE OPINION FOR SLEEPING SICKNESS Source text: nGNE9zmflt Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes